{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:44:00Z","timestamp":1788957840497,"version":"build-2803163510"},"reference-count":98,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cannabis &amp; Cannabinoid Research"],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>\n                      Opioid use disorder (OUD) is a major public health crisis worldwide. Patients with OUD inevitably experience withdrawal symptoms when they attempt to taper down on their current opioid use, abstain completely from opioids, or attempt to transition to certain medications for opioid use disorder. Acute opioid withdrawal can be debilitating and include a range of symptoms such as anxiety, pain, insomnia, and gastrointestinal symptoms. Whereas acute opioid withdrawal only lasts for 1\u20132 weeks, protracted withdrawal symptoms can persist for months after the cessation of opioids. Insufficient management of opioid withdrawal often leads to devastating results including treatment failure, relapse, and overdose. Thus, there is a critical need for cost-effective, nonopioid medications, with minimal side effects to help in the medical management of opioid withdrawal syndrome. We discuss the potential consideration of cannabidiol (CBD), a nonintoxicating component of the cannabis plant, as an\n                      <jats:italic toggle=\"yes\">adjunctive<\/jats:italic>\n                      treatment in managing the opioid withdrawal syndrome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>A review of the literature was performed using keywords related to CBD and opioid withdrawal syndrome in PubMed and Google Scholar. A total of 144 abstracts were identified, and 41 articles were selected where CBD had been evaluated in clinical studies relevant to opioid withdrawal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>CBD has been reported to have several therapeutic properties including anxiolytic, antidepressant, anti-inflammatory, anti-emetic, analgesic, as well as reduction of cue-induced craving for opioids, all of which are highly relevant to opioid withdrawal syndrome. In addition, CBD has been shown in several clinical trials to be a well-tolerated with no significant adverse effects, even when co-administered with a potent opioid agonist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Growing evidence suggests that CBD could potentially be added to the standard opioid detoxification regimen to mitigate acute or protracted opioid withdrawal-related symptoms. However, most existing findings are either based on preclinical studies and\/or small clinical trials. Well-designed, prospective, randomized-controlled studies evaluating the effect of CBD on managing opioid withdrawal symptoms are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/can.2021.0089","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T16:24:18Z","timestamp":1634919858000},"page":"569-581","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":19,"title":["Adjunctive Management of Opioid Withdrawal with the Nonopioid Medication Cannabidiol"],"prefix":"10.1177","volume":"7","author":[{"given":"Christopher","family":"Kudrich","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Addiction Institute of Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, New York, USA."},{"name":"Mount Sinai Beth Israel Hospital, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin L.","family":"Hurd","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Addiction Institute of Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Salsitz","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Addiction Institute of Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, New York, USA."},{"name":"Mount Sinai Beth Israel Hospital, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0938-5157","authenticated-orcid":false,"given":"An-Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Addiction Institute of Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). Key substance use and mental health indicators in the United States: results from the 2018 national survey on drug use and health. HHS publication no PEP19-5068 2019;NSDUH Series H-54. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/cbhsq-reports\/NSDUHNationalFindingsReport2018\/NSDUHNationalFindingsReport2018.pdf Accessed August4 2019."},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/adaw.33143","article-title":"CDC: 93,000 deaths from drug overdoses in the US in 2020","volume":"33","author":"Knopf A","year":"2021","unstructured":"Knopf A. CDC: 93,000 deaths from drug overdoses in the US in 2020. Alcohol Drug Abuse Wkly. 2021; 33:4\u20136.","journal-title":"Alcohol Drug Abuse Wkly"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0899-3289(92)90024-R"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2016.03.028"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2003.10400007"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-1-200007040-00008"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.150.5.695"},{"key":"e_1_3_4_9_2","first-page":"1","article-title":"Protracted withdrawal","volume":"9","author":"Center for Substance Abuse Treatment","year":"2010","unstructured":"Center for Substance Abuse Treatment. Protracted withdrawal. Subst Abuse Treat Advis. 2010; 9:1\u20138.","journal-title":"Subst Abuse Treat Advis"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2008.04.033"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.04.022"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-018-0108-7"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.03.004"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2017.1312644"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12862"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.10.002"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1402780"},{"key":"e_1_3_4_18_2","unstructured":"Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs. Substance Abuse and Mental Health Services Administration: Rockville (MD) 2005."},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16050548"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-016-0087-9"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019828954"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000473"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2020.22.3\/rspanagel"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.21-03-00823.2001"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2008.09.027"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13250"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-006-0033-x"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00426828"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(75)90435-X"},{"key":"e_1_3_4_30_2","first-page":"185","article-title":"Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats","volume":"12","author":"Hine B","year":"1975","unstructured":"Hine B, , Torrelio M, , Gershon S. Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats. Res Commun Chem Pathol Pharmacol. 1975; 12:185\u2013188.","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.02.041"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.18101191"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.20977"},{"key":"e_1_3_4_34_2","first-page":"6","article-title":"Case report: cannabidiol in the management of acute opioid withdrawal","volume":"3","author":"Shaw C","year":"2021","unstructured":"Shaw C, , Marcu J. Case report: cannabidiol in the management of acute opioid withdrawal. Am J Endocannabinoid Med. 2021; 3:6\u201311.","journal-title":"Am J Endocannabinoid Med"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-015-0373-7"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000118"},{"key":"e_1_3_4_37_2","unstructured":"World Health Organization. Cannabidiol (CBD) critical review report. : WHO: Geneva Switzerland 2018."},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1080\/14659891.2019.1659868"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1089\/can.2019.0052"},{"key":"e_1_3_4_40_2","author":"Appiah-Kusi E","year":"2020","unstructured":"Appiah-Kusi E, , Petros N, , Wilson R, et al. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology. 2020:1\u201310.","journal-title":"Psychopharmacology"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2011.6"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2009.184"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110379283"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300340"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1590\/1516-4446-2017-0015"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2019.02466"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00259"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/18-041"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2008.519"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-012-2955-y"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1089\/can.2017.0014"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881117737400"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161212802884780"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2019.11.008"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00561"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1089\/can.2016.0007"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1191\/0269215503cr581oa"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1089\/can.2019.0079"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.2174\/157488611798280924"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1089\/can.2016.0034"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8070989"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2019.1685298"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2017.12.042"},{"key":"e_1_3_4_64_2","first-page":"4","article-title":"Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand","author":"Gulbransen G","year":"2020","unstructured":"Gulbransen G, , Xu W, , Arroll B. Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand. BJGP Open. 2020; 4.","journal-title":"BJGP Open"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389201020666191202111534"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.2004.03674.x"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001464"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4291-09.2009"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00773-x"},{"key":"e_1_3_4_70_2","first-page":"34","article-title":"Cannabidiol use in older adults","volume":"45","author":"Calderon B","year":"2020","unstructured":"Calderon B, , Sayre T. Cannabidiol use in older adults. US Pharm. 2020; 45:34\u201338.","journal-title":"US Pharm"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1981.tb02622.x"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01521"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01145"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00315"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01621.x"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-05012-8"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-005-6978-1"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.020"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1739-9"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30136-3"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01639.x"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.1179\/016164109X12590518685660"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0720-6"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511419700"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03328.x"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458505070618"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.1191\/1352458504ms1082oa"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14225"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93760"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119895536"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1002\/jat.3440"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7620860"},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2013.04.002"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom10111575"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.1089\/can.2017.0047"},{"key":"e_1_3_4_96_2","doi-asserted-by":"publisher","DOI":"10.1089\/can.2017.0043"},{"key":"e_1_3_4_97_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-019-05756-7"},{"key":"e_1_3_4_98_2","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13815"},{"key":"e_1_3_4_99_2","author":"Wise J.","unstructured":"Wise J. FDA approves its first cannabis based medicine, BMJ 2018;361. https:\/\/doi.org\/10.1136\/bmj.k2827","journal-title":"BMJ"}],"container-title":["Cannabis &amp; Cannabinoid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/can.2021.0089","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/can.2021.0089","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/can.2021.0089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:11:25Z","timestamp":1777385485000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/can.2021.0089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":98,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10,1]]}},"alternative-id":["10.1089\/can.2021.0089"],"URL":"https:\/\/doi.org\/10.1089\/can.2021.0089","relation":{},"ISSN":["2578-5125","2378-8763"],"issn-type":[{"value":"2578-5125","type":"print"},{"value":"2378-8763","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,1]]}}}